Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment
NCT ID: NCT02921698
Last Updated: 2018-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2014-07-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Analysis of FRED™/FRED™Jr Embolic Device in Aneurysm Treatment
NCT03423290
FRED and FRED JR Devices for Intracranial Aneurysm Treatment
NCT04315168
FRED Retrospective Study of Intracranial Aneurysms Treatment
NCT06982781
Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms
NCT01801007
Canadian Study of the MicroVention Flow Re-Direction (FRED) Endoluminal Device Stent System in the Treatment of Intracranial Aneurysms
NCT02309203
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FRED®
FRED®
Flow Re-Direction Endoluminal Device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FRED®
Flow Re-Direction Endoluminal Device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient has an unruptured or recanalized intracranial aneurysm :
* for which an endovascular treatment has been determined appropriate
* that can not be treated by standard techniques (coiling with or without remodeling)
* and for which the FRED® Flow Diverter has been determined an appropriate treatment
3. Patient or patient's legally authorized representative has been informed about the confidentiality of the study and agrees to the collection of his/her personal data
4. Patient presents with an mRS score between 0 and 2
5. Patients who have already been treated with a stent or a flow diverter for another aneurysm may be included if:
* the previous treatment was more than three months prior to enrollment in this study
* the aneurysm to be treated for this study is a new aneurysm located on a different parent vessel unless the stent already in place is implanted on the proximal carotid artery.
Exclusion Criteria
2. Patient has contraindication to antiplatelet therapy and/or heparin
3. Patient is pregnant and/or breastfeeding
4. Patient may not benefit from imaging and clinical monitoring
5. Patient has a medical or surgical co-morbidities limiting his/her life expectancy to less than 1 year
6. Patient will be treated with a flow diverter other than FRED®
7. Patient had an intracranial hemorrhage within the 30 days preceding treatment
8. Patient has an aneurysm(s) with one or more of the following characteristics:
* associated with an arteriovenous malformation
* dissecting or ""blister-like""
* multiple (unless only one aneurysm requires treatment)
* located in the posterior circulation
* treated with a stent or a flow diverter on the same parent vessel (excluding proximal carotid artery) or in the 3 months prior to inclusion
9. Patient has stenosis of the aneurysm parent artery.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Microvention-Terumo, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurent Pierot, Prof.
Role: PRINCIPAL_INVESTIGATOR
CHU Reims; Reims, France
References
Explore related publications, articles, or registry entries linked to this study.
Pierot L, Spelle L, Berge J, Januel AC, Herbreteau D, Aggour M, Piotin M, Biondi A, Barreau X, Mounayer C, Papagiannaki C, Lejeune JP, Gauvrit JY, Derelle AL, Chabert E, Costalat V. SAFE study (Safety and efficacy Analysis of FRED Embolic device in aneurysm treatment): 1-year clinical and anatomical results. J Neurointerv Surg. 2019 Feb;11(2):184-189. doi: 10.1136/neurintsurg-2018-014261. Epub 2018 Oct 8.
Pierot L, Spelle L, Berge J, Januel AC, Herbreteau D, Aggour M, Piotin M, Biondi A, Barreau X, Mounayer C, Papagiannaki C, Lejeune JP, Gauvrit JY, Costalat V. Feasibility, complications, morbidity, and mortality results at 6 months for aneurysm treatment with the Flow Re-Direction Endoluminal Device: report of SAFE study. J Neurointerv Surg. 2018 Aug;10(8):765-770. doi: 10.1136/neurintsurg-2017-013559. Epub 2018 Jan 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAFE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.